Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) shares dropped 0% on Friday . The stock traded as low as $3.55 and last traded at $3.56, with a volume of 158,742 shares traded. The stock had previously closed at $3.56.

ARLZ has been the topic of several research analyst reports. Chardan Capital decreased their price target on shares of Aralez Pharmaceuticals from $15.50 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, March 16th. Dundee Securities decreased their price target on shares of Aralez Pharmaceuticals from $10.00 to $9.00 and set a “buy” rating on the stock in a report on Wednesday, March 16th.

The stock has a 50-day moving average price of $3.66 and a 200-day moving average price of $4.76. The company’s market capitalization is $231.11 million.

Aralez Pharmaceuticals (NASDAQ:ARLZ) last announced its quarterly earnings results on Tuesday, May 10th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by $0.48. The business had revenue of $8.10 million for the quarter, compared to the consensus estimate of $9.70 million. The business’s quarterly revenue was up 84.1% compared to the same quarter last year. On average, analysts anticipate that Aralez Pharmaceuticals Inc. will post ($1.00) EPS for the current year.

In other Aralez Pharmaceuticals news, insider James Patrick Tursi bought 10,000 shares of Aralez Pharmaceuticals stock in a transaction dated Friday, May 20th. The shares were purchased at an average cost of $3.75 per share, for a total transaction of $37,500.00. Following the acquisition, the insider now directly owns 179,368 shares in the company, valued at approximately $672,630. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Andrew I. Koven bought 71,500 shares of Aralez Pharmaceuticals stock in a transaction dated Thursday, May 12th. The stock was acquired at an average price of $3.49 per share, for a total transaction of $249,535.00. Following the completion of the acquisition, the insider now owns 1,610,306 shares in the company, valued at $5,619,967.94. The disclosure for this purchase can be found here.

Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.